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Maintenance of Gains, Morbidity, and Mortality at 1 Year Following
Cardiac Rehabilitation in a Middle-Income Country: A Wait-List
Control Crossover Trial
Gabriela S. S. Chaves, PhD; Gabriela Lima de Melo Ghisi, PhD; Raquel R. Britto, PhD; Sherry L. Grace, PhD, FCCS
Background-—Despite the epidemic of cardiovascular diseases in middle-income countries, few trials are testing the beneﬁts of
cardiac rehabilitation (CR). This trial assessed (1) maintenance of functional capacity, risk factor control, knowledge, and heart-
health behaviors and (2) mortality and morbidity at 6 months following CR in a middle-income country.
Methods and Results-—Eligible Brazilian coronary patients were initially randomized (1:1:1 concealed) to 1 of 3 parallel arms
(comprehensive CR [exercise plus education], exercise-only CR, or wait-list control). The CR programs were 6 months in duration,
at which point follow-up assessments were performed. Mortality and morbidity were ascertained from chart and patient or family
report (blinded). Controls were then offered CR (crossover). Outcomes were again assessed 6 months later (blinded). ANCOVA was
performed for each outcome at 12 months. Overall, 115 (88.5%) patients were randomized, and 62 (53.9%) were retained at
1 year. At 6 months, 23 (58.9%) of those 39 initially randomized to the wait-list control elected to attend CR. Functional capacity,
risk factors, knowledge, and heart-health behaviors were maintained from 6 to 12 months in participants from both CR arms (all
P>0.05). At 1 year, knowledge was signiﬁcantly greater with comprehensive CR at either time point (P<0.001). There were 2
deaths. Hospitalizations (P=0.03), nonfatal myocardial infarctions (P=0.04), and percutaneous coronary interventions (P=0.03)
were signiﬁcantly fewer with CR than control at 6 months.
Conclusions-—CR participation is associated with lower morbidity, long-term maintenance of functional capacity, risk factors, and
heart-health behaviors, as well as with greater cardiovascular knowledge compared with no CR.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT02575976. ( J Am Heart Assoc. 2019;8:
e011228. DOI: 10.1161/JAHA.118.011228.)
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C ardiovascular diseases are among the leading burdens ofdisease globally and are the leading cause of death, with
>80% of these deaths occurring in low- and middle-income
countries (LMICs)1 such as Brazil.2 Cardiac rehabilitation (CR)
is an outpatient model of secondary prevention designed to
mitigate this burden.3
CR comprises internationally agreed core components
including structured exercise and patient education.3,4 Meta-
analyses demonstrate that participation in CR is associated
with 20% lower morbidity and cardiovascular mortality
compared with usual care.5 However, included trials were all
undertaken in high-income countries, and there have been no
trials with mortality or morbidity outcomes in an LMIC to our
knowledge. This is a major knowledge gap, considering that
resources in many LMICs are so limited that only the core
component of exercise is offered; thus, a pragmatic trial is
greatly needed. Moreover, recent meta-analyses have ques-
tioned the impact of CR on all-cause mortality in the current
era.5,6 The responses to the review by Powell et al6 suggested
that such beneﬁts would likely be observed in LMICs,3 given
the lack of preventive care, risk factor management, and other
differences with high-income countries.7
Reduced mortality and morbidity in the long term are likely
achieved through maintenance of heart-health behavior
changes initiated through CR, ensuring sustained risk factor
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control. Consequently, the objectives of this study were (1) to
assess maintenance of functional capacity, risk factor control,
knowledge, and heart-health behaviors in the 6 months
following CR (exercise-only or comprehensive CR [CCR]) versus
usual care, (2) to test the effects of CR on mortality and
morbidity at 6 months after the program in a middle-income
country. It was hypothesized that patients who participate in
CR, compared with patients who do not participate, maintain
their gains and have lower mortality and morbidity.
Methods
Design
Research ethics approval was obtained from Federal Univer-
sity of Minas Gerais (898.235) and York University (e2015–
172). The data that support the ﬁndings of this study may be
made available in anonymized form by the corresponding
author on reasonable request from qualiﬁed researchers
trained in human subject conﬁdentiality protocols, with
appropriate research ethics approvals and secure data
transfer agreements. This article presents secondary analysis
of trial data, focusing on the mortality and morbidity
outcomes that have not been previously reported, as well as
primary, secondary, and tertiary outcomes of the trial
reported not only from the prespeciﬁed 6-month end point
(corresponding with the end of CR for those in the
intervention arms) but also longer term at 12 months from
initial randomization.
A single-blinded, single-site, pragmatic, superiority random-
ized controlled trial was undertaken with 3 parallel arms: CCR
(education and exercise), exercise-only CR (no education), and
wait-list control (ie, no CR). Patient assessments were per-
formed before randomization and 6 months later. A detailed
protocol8 and primary and secondary9 outcomes at 6 months
are reported elsewhere.Mortality andmorbidity (the latter being
added after trial commencement) were also assessed at
6 months.
After the 6-month assessments, the wait-list control group
was offered CR (exercise only or CCR; ie, nonrandomized
crossover; Figure 1) by a doctoral student (G.C.). Although not
envisioned when the original protocol was designed, assess-
ments of all outcomes, including mortality and morbidity, were
undertaken again in all participants at 12 months from trial
inception. Thus, the 5 conditions were exercise-only CR, CCR
(both of these conditions would be expected to have carryover
effects, but no more CR sessions were offered after the 6-
month program), wait-list control (and did not elect to
participate in CR at posttest), exercise-only CR after
6 months, and CCR after 6 months.
Setting
This randomized controlled trial was conducted in the
Brazilian city of Belo Horizonte, in the publicly funded
academic center Hospital das Clınicas of the Universidade
Federal de Minas Gerais. The wait-list control group received
usual care, which consists of patients’ follow-up appointments
with their physician as deemed medically appropriate. The
standard of care for Brazilian adults with cardiovascular
disease does not include access to CR, given the gross lack of
capacity.10
Intervention Arms
The CR program is led by a physician and staffed by
physiotherapists. Participants underwent an initial assess-
ment including functional capacity and risk factors at intake.
The exercise program was 6 months in duration, consisting
of 36 1-hour supervised sessions offered in descending
frequency.8 Each CR participant received an individualized
exercise prescription based on a graded exercise stress test.
Patients were requested to exercise in their communities on
the days they were not on-site so as to accumulate ≥30
minutes of physical activity at moderate to vigorous intensity
on ≥5 days per week, as recommended in practice guide-
lines.3,4,11
In the CCR arm, 24 education sessions were also offered,
each of 30-minute duration. Sessions were delivered weekly, in
a group setting, by a health educator, in Brazilian Portuguese.8
Participants received a validated education workbook to
accompany the sessions (https://www.healtheuniversity.ca/
pt/CardiacCollege/About/Pages/download-guide.aspx).12
Clinical Perspective
What Is New?
• Cardiac rehabilitation participation was associated with
lower morbidity and with maintenance of functional capac-
ity, risk factors, and heart-health behaviors at 6 months
after the program compared with no cardiac rehabilitation.
• Comprehensive cardiac rehabilitation was associated with
signiﬁcantly greater knowledge.
What Are the Clinical Implications?
• Broader implementation of comprehensive cardiac rehabil-
itation services is needed.
• Despite the epidemic of cardiovascular disease in middle-
income countries, the sustained impact of cardiac rehabil-
itation in mitigating this burden was unknown in these
settings.
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Participants
Patients with coronary artery disease after myocardial infarc-
tion (MI) or those who had undergone percutaneous coronary
intervention (PCI) or coronary artery bypass grafting and were
referred to CR were eligible to participate in the trial. The
inclusion criteria were patients aged >18 years and living in the
Belo Horizonte area. The exclusion criteria were cardiac
conditions associated with some risk during high-intensity
exercise (eg, heart failure with ejection fraction <45%, complex
ventricular dysrhythmia), any comorbid physical condition (eg,
leg amputation, advanced cancer, disabling stroke, Parkinson’s
disease) or serious mental illness that would interfere with the
ability to exercise, according to CR clinical practice guidelines,
or any visual or cognitive condition that would preclude the
participant from completing the questionnaires.
Sample size calculations were performed for the primary
outcome of functional capacity at 6 months, namely,
distance walked (see Measures).8 Based on previous studies,
we considered 70 m a clinically important difference and
assumed a standard deviation of 139 m. In accordance, 62
participants were required per group to ensure 80% power at
the 5% signiﬁcance level to detect a statistically signiﬁcant
difference.
Procedures
A doctoral student (G.C.) approached consecutive patients
during the ﬁrst physician consultation after hospital discharge
from March 2015 to April 2017. With informed written consent
from the patient and CR clearance from the physician, eligible
participants were scheduled to come on-site to complete
Figure 1. Study ﬂow diagram. The threshold number of sessions for per-protocol analysis was minimum
of 24 of 36 exercise sessions (both CR arms) and an additional 16 of 24 education classes for
comprehensive CR. CR indicates cardiac rehabilitation.
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pretest assessments. This included completion of a survey and
instruction on wearing the pedometer. Follow-up assessments
were performed between September 2015 and May 2018.
Randomization and Blinding
Eligible participants were initially randomized to 1 of the 3 arms:
wait-list control, exercise-only CR, and CCR. The randomization
sequence was generated using the Randomization.com website
in random blocks of 4, with a 1:1:1 allocation ratio. To ensure
allocation concealment, the local principal investigator (R.B.)
has the allocation sequence in a password-protected ﬁle and
randomization information was provided to the doctoral student
(G.C.) once the participant was conﬁrmed to be eligible. Because
of the nature of the intervention, the participants and the
doctoral student could not be blind to treatment allocation.
Figure 2. Mortality and morbidity by arm and time. The threshold number of sessions for per-protocol
analysis was minimum of 24of 36 exercise sessions (both CR arms) and an additional 16 of 24 education
classes for CCR. Least signiﬁcant difference post hoc: *§P<0.05; **P<0.01. CABG indicates coronary artery
bypass grafting; CCR, comprehensive cardiac rehabilitation; CR, cardiac rehabilitation; CV, cardiovascular;
Dept, department; MI, myocardial infarction; PCI, percutaneous coronary intervention.
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
DOI: 10.1161/JAHA.118.011228 Journal of the American Heart Association 4
Morbidity and Mortality After CR in an LMIC Chaves et al
D
ow
nloaded from
 http://ahajournals.org by on March 9, 2020
Table 1. Participants’ Baseline Sociodemographic and Clinical Characteristics by Condition
Initial Randomization Wait-List Control (n=39)
Exercise
Only (n=39)
Comprehensive
(n=37)
Total (N=115)Disposition at 6 mo
No CR
(n=16)
Exercise
Only (n=12)
Comprehensive
(n=11) No CR No CR
Sociodemographic
Sex (male) 11 (68.8) 12 (100.0)†† 4 (36.4)†† 28 (71.8) 27 (73.0) 82 (71.3)‡
Age, y 55.96.7 60.713.3 60.68.4 59.09.9 60.78.8 59.59.4
Education (low)§ 9 (56.3)* 10 (83.3) 9 (81.8) 33 (84.6)*†† 21 (56.8)†† 82 (71.3)‡
Marital status
(married or equivalent)**
9 (56.3) 9 (75.0) 9 (81.8) 27 (69.2) 20 (54.1) 74 (64.3)
Work status (employed) 11 (68.8) 3 (25.0) 3 (27.3) 14 (35.9) 15 (40.5) 46 (40.0)
Monthly income (low)k 13 (81.3) 11 (91.7) 11 (100.0) 34 (87.2) 31 (83.8) 100 (87.0)
Clinical
CR indication (yes)
MI 15 (93.8) 11 (91.7) 9 (81.8) 37 (94.9) 35 (94.6) 107 (93.0)
Angina 12 (75.0) 8 (66.7) 7 (63.6) 21 (53.8) 21 (56.8) 69 (60.0)
PCI 10 (62.5) 9 (75.0) 4 (36.4) 23 (59.0) 22 (59.5) 68 (59.1)
Bypass surgery 3 (18.8) 4 (33.3) 3 (27.3) 7 (17.9) 12 (32.4) 29 (25.2)
First event (no) 4 (25.0) 2 (16.7) 2 (18.2) 8 (21.1) 12 (32.4) 28 (24.8)
Comorbidities (yes)
Depression 3 (18.8) 2 (16.7) 2 (18.2) 7 (17.9) 6 (16.2) 20 (17.4)
Kidney disease 1 (6.3) 2 (16.7) 1 (9.1) 3 (7.7) 6 (16.2) 13 (11.3)
Liver disease 0 (0.0) 1 (8.3) 0 (0.0) 2 (5.1) 5 (13.5) 8 (7.0)
Rheumatic disease 1 (6.3) 2 (16.7) 1 (9.1) 1 (2.6) 2 (5.4) 7 (6.1)
Cancer 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.6) 5 (13.5) 6 (5.2)
Stroke 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.6) 2 (5.4) 3 (2.6)
COPD 0 (0.0) 0 (0.0) 0 (0.0) 3 (7.7) 0 (0.0) 3 (2.6)
Functional capacity
Stress test (HR max, bpm) 118.721.2 125.321.4 112.417.2 124.821.4 120.424.2 121.421.9
Stress test (peak METs) 7.22.7 7.92.3 6.61.9 7.72.6 7.82.6 7.62.5
ISWT, m 380.6111.6 443.3186.6 297.3106.4 361.0119.4 381.1120.9 372.7128.5
Risk factors
BP systolic, mm Hg 115.021.6 117.59.6 122.718.5 117.324.7 123.815.1 119.619.6
BP diastolic, mm Hg 75.017.5 71.711.1 77.319.0 77.713.0 77.011.0 76.413.5
BMI, kg/m2 27.54.2 27.63.7 28.64.5 28.76.0 28.14.2 28.24.8
WC, cm 93.010.1 96.811.4 95.57.4 96.710.6 96.011.5 95.910.6
TC, mg/dL 137.329.0 154.240.3 165.430.2 148.739.4 165.061.9 155.746.9
LDL, mg/dL 68.821.2 84.138.9 93.324.3 80.423.7 86.429.7 83.127.9
HDL, mg/dL 42.66.5 39.37.5 44.26.8 40.414.3 39.57.9 40.710.1
Triglycerides, mg/dL 134.157.5 152.944.1 136.455.0 137.775.2 166.0117.0 148.685.6
Glucose (fasting),
mg/dL
106.325.6 110.834.8 112.252.5 107.235.3 104.620.2 107.332.0
Sleep apnea (yes) 2 (12.5) 2 (16.7) 1 (9.1) 4 (10.3) 4 (10.8) 13 (11.3)
Smoking (current) 1 (6.3) 1 (8.3) 0 (0.0) 4 (10.3) 3 (8.1) 9 (7.8)
Continued
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Master’s degree students blinded to random allocation
undertook subsequent 6- and 12-month assessments, out-
come ascertainment, and data entry. To minimize loss to
follow-up, patients were called to remind them to come on-
site for these assessments.
Measures
Participants were asked to complete a sociodemographic
questionnaire at baseline. Clinical characteristics were
extracted from medical charts, including sex, age, risk factors,
cardiac history, laboratory test results, comorbidities, and
medications. CR session attendance (both exercise and
education sessions) was extracted from program charts for
participants at 6 months.
The primary outcome of the trial was functional capacity
(incremental shuttle walk test; 7 metabolic equivalents of task
was considered indicative of independent living and thus was
the target).13 Secondary outcomes were risk factors (ie, blood
pressure at rest; high blood pressure was considered at target
if values were either <140 mm Hg systolic or <90 diastolic11),
lipids (not assessed at 12 months), anthropometrics (those
with body mass index <30 were considered at practice
guideline target11; waist circumference of <102 cm in men
and <88 cm in women were considered at guideline target for
central obesity14), and depressive symptoms (Patient Health
Questionnaire-9; scores ≤10 considered subclinical and thus
at target).15,16 Tertiary outcomes were cardiovascular disease
knowledge,17 heart-health behaviors (ie, exercise, diet,18 and
smoking [self-report]), and mortality. Exercise was assessed
via pedometer. Willing participants wore a Digi-Walker SW200
(Yamax) 19–22 for 7 days at each assessment point. Mean
steps per week was computed, with ≥7500 steps/day
considered commensurate with the guideline target for
150 minutes/week in populations with chronic disease.23
Mortality (all-cause and cardiovascular) and morbidity were
ascertained at 6 and 12 months from baseline. Morbidity
included emergency department visits for cardiac causes,
hospital admissions for cardiac causes, nonfatal MI, angina,
revascularization (PCI or coronary artery bypass grafting), or
heart failure. These data were obtained from the center’s health
system records and were supplemented by participant report
(and/or family via phone if participants had died or did not
come on-site for the 12-month assessment) to capture deaths,
cardiac events, and procedures that may have occurred outside
the hospital. Reason for death also was recorded when
available. A form was developed to standardize the verbal
interviewer-administered assessment and was piloted.
Table 1. Continued
Initial Randomization Wait-List Control (n=39)
Exercise
Only (n=39)
Comprehensive
(n=37)
Total (N=115)Disposition at 6 mo
No CR
(n=16)
Exercise
Only (n=12)
Comprehensive
(n=11) No CR No CR
Medications (yes)
Statins 16 (100.0) 12 (100.0) 10 (90.9) 37 (94.9) 36 (97.3) 111 (98.2)
ASA 16 (100.0) 10 (83.3) 10 (90.9) 35 (92.1) 35 (97.2) 106 (94.6)
b-Blockers 16 (100.0) 11 (91.7) 10 (90.9) 30 (78.9) 33 (91.7) 100 (89.3)
Antiplatelets 13 (81.3) 7 (58.3) 8 (72.7) 30 (78.9) 23 (63.9) 81 (72.3)
ACEIs 6 (37.5) 7 (58.3) 7 (63.6) 26 (68.4) 27 (75.0) 73 (65.2)
ARBs 6 (37.5) 5 (41.7) 1 (9.1) 8 (21.1) 6 (16.7) 26 (23.2)
Other
Cardiac knowledge¶ 45.914.4 43.919.1 46.49.9 48.2413.3 51.2411.9 48.3213.5
Exercise (steps/wk) 32 898.5
17 657.3
28 047.0
18 558.8
31 582.8
14 555.0
33 153.1
27 636.6
31 415.0
23 918.4
31 855.1
23 027.5
Diet# 10.15.8 9.27.7 3.45.7 5.927.4 4.657.7 6.187.4
Data are shown as n (%) or meanSD. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; BP,
blood pressure; bpm, beats/minute; COPD, chronic obstructive pulmonary disease; CR, cardiac rehabilitation; HDL, high-density lipoprotein; HR, heart rate; ISWT, incremental shuttle walk
test; LDL, low-density lipoprotein; MET, metabolic equivalent of task; MI, myocardial infarction; PCI, percutaneous coronary intervention; TC, total cholesterol; WC, waist circumference.
Bonferroni post hoc tests: *†one symbol P<0.05; 2 symbols P<0.01.
ANOVA or Fisher exact test for characteristic by condition ‡P<0.05.
**ie, living together for many years, although not ofﬁcially married.
§Did not complete high school.
kLess than 4 minimum wages per month.
¶Scores on the Coronary Artery Disease Questionnaire23 range from 0 to 93, with higher scores indicating better knowledge.
#Scores on the Food Frequency Questionnaire range from 36 to +47, with higher scores indicating better diet.
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Table 2. Participants’ Baseline Sociodemographic and Clinical Characteristics by Retention at 12-Month Assessment
Characteristic Retained (n=62; 53.9%) Lost to Follow-up (n=53; 46.1%) Total (n=115)
Sociodemographic
Sex (male) 44 (71.0) 38 (71.7) 82 (71.3)
Age, y 60.09.8 58.99.0 59.59.4
Education (low)* 48 (77.4) 34 (64.2) 82 (71.3)
Marital status (married or equivalent)** 45 (72.6) 29 (54.7) 74 (64.3)†
Work status (employed) 20 (32.3) 26 (49.1) 46 (40.0)
Monthly income (low)‡ 56 (90.3) 44 (83.0) 100 (87.0)
Clinical
CR indication (yes)
MI 57 (91.9) 50 (94.3) 107 (93.0)
Angina 41 (66.1) 28 (52.8) 69 (60.0)
PCI 40 (64.5) 28 (52.8) 68 (59.1)
Bypass surgery 17 (27.4) 12 (22.6) 29 (25.2)
First event (no) 15 (24.6) 13 (25.0) 28 (24.8)
Comorbidities (yes)
Depression 8 (12.9) 12 (22.6) 20 (17.4)
Kidney disease 9 (14.5) 4 (7.5) 13 (11.3)
Liver disease 6 (9.7) 2 (3.8) 8 (7.0)
Rheumatic disease 5 (8.1) 2 (3.8) 7 (6.1)
Cancer 3 (4.8) 3 (5.7) 6 (5.2)
Stroke 1 (1.6) 2 (3.8) 3 (2.6)
COPD 2 (3.2) 1 (1.9) 3 (2.6)
Functional capacity
Stress test (HR max), bpm 120.323.1 122.720.7 121.421.9
Stress test (peak METs) 7.72.5 7.42.5 7.62.5
ISWT, m 375.3128.9 369.6129.2 372.7128.5
Risk factors
BP systolic, mm Hg 119.315.5 119.923.8 119.619.6
BP diastolic, mm Hg 74.712.4 78.514.6 76.413.5
BMI, kg/m2 28.55.4 27.94.2 28.24.8
WC, cm 96.610.5 95.010.7 95.910.6
TC, mg/dL 159.040.3 151.254.8 155.746.9
LDL, mg/dL 88.132.1 76.720.0 83.127.9
HDL, mg/dL 41.111.5 40.18.1 40.710.1
Triglycerides, mg/dL 148.960.2 148.1112.8 148.685.6
Glucose (fasting), mg/dL 112.637.3 100.923.1 107.332.0
Sleep apnea 11 (17.7) 2 (3.8) 13 (11.3)†
Smoking (current) 6 (9.7) 3 (5.7) 9 (7.8)
Medications
Statins 60 (96.8) 51 (96.2) 111 (98.2)
ASA 57 (91.9) 49 (92.4) 106 (94.6)
b-Blockers 53 (85.5) 47 (88.7) 100 (89.3)
Continued
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Statistical Analysis
SPSS v24.0 (IBM Corp) was used, and the level of signiﬁcance
was set at P=0.05 for all tests. Before outcome analysis,
differences in participants’ baseline sociodemographic and
clinical characteristics were compared among the 5 condi-
tions using Fisher exact tests and ANOVA, as appropriate.
Moreover, the retention rate was computed, and differences
in the sociodemographic and clinical characteristics of
participants who were retained (ie, completed 12-month
assessment) versus lost to follow-up were compared using
Fisher exact tests and t tests, as appropriate.
Participants were included in the per-protocol analyses if
they met the threshold number of ≥24 exercise sessions in
the exercise-only arm and, additionally, ≥16 educational
sessions in the CCR arm at the 6-month assessment.
Nevertheless, analyses were ﬁrst performed on the basis of
intention to treat (using last observation carried forward for all
outcomes except morbidity; at the 12-month assessment,
wait-listed participants who elected CR were analyzed as
treated; see Figures 1 and 2).
To test the ﬁrst objective, maintenance of functional
capacity, risk factors, and heart-health behavior from 6 to
12 months within condition was assessed using the paired t
test (nonparametric test [Wilcoxon signed rank test]) for
pedometer step counts, which were not normally distributed;
outcomes were considered “maintained” if there was no
signiﬁcant difference in 6- and 12-month scores (ie, P>0.05).
To test the second objective, ANCOVA (adjusting for char-
acteristics that differed by condition or retention, as
assessed earlier) was performed for each of the outcomes
at 12 months (except smoking, for which a Fisher exact test
was performed), with condition (ie, 5) as the independent
variable. Least signiﬁcant difference post hoc tests were
performed if signiﬁcant differences were observed. Finally, to
account for period effects, outcomes were described by
condition regardless of time point (ie, outcomes for exercise
only in those randomized to this arm at 6 months and in wait-
list controls electing exercise only at 12 months).
For mortality and morbidity, frequencies (and means for
the latter) were calculated by arm and condition (ie, 3 arms at
6 months and 5 conditions at 12 months) for both follow-up
assessment points. Differences were tested using Fisher
exact tests and ANOVA.
Results
Respondent Characteristics
A participant ﬂow diagram is shown in Figure 1. The consent
rate was very high, and 115 patients were randomized.
Randomization was effective in ensuring equivalence across
arms in most instances (only differences were in educational
attainment and comorbid cancer).9 At 6 months, 93 (80.9%)
were retained. There was no clinical bias and minimal
sociodemographic bias in the retained sample, except that
those retained were signiﬁcantly older and less likely to be
working than those lost to follow-up.9
At 6 months, of those initially randomized to the wait-list
control, 12 (30.8%) elected to attend exercise-only CR and 11
(28.2%) chose CCR (Figure 1). Table 1 presents baseline
participant characteristics by condition. Only signiﬁcant
differences were noted for sex (more male participants chose
exercise-only CR than CCR after 6 months) and education
(those retained in the exercise-only CR arm initially were
signiﬁcantly more educated than retained participants both
Table 2. Continued
Characteristic Retained (n=62; 53.9%) Lost to Follow-up (n=53; 46.1%) Total (n=115)
Antiplatelet 43 (69.3) 38 (71.7) 81 (72.3)
ACEIs 42 (67.7) 31 (58.5) 73 (65.2)
ARBs 16 (25.8) 10 (18.9) 26 (23.2)
Other
Cardiac knowledge§ 49.013.2 47.513.8 48.3213.46
Exercise (steps/d) 29 781.320 435.2 34 287.925 729.9 4550.73289.6
Dietk 6.47.5 5.97.2 6.187.38
Data are shown as n (%) or meanSD. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; ASA, acetylsalicylic acid; BMI, body mass index; BP,
blood pressure; bpm, beats per minute; COPD, chronic obstructive pulmonary disease; CR, cardiac rehabilitation; HDL, high-density lipoprotein; HR, heart rate; ISWT, incremental shuttle
walk test; LDL, low-density lipoprotein; MET, metabolic equivalent of task; MI, myocardial infarction; PCI, percutaneous coronary intervention; TC, total cholesterol; WC, waist
circumference.
*Did not complete high school.
**ie, living together for many years, although not ofﬁcially married.
†Unpaired t test: P<0.05.
‡Less than 4 minimum wages per month.
§Scores on the Coronary Artery Disease Questionnaire range from 0 to 93, with higher scores indicating better knowledge.
kScores on the Food Frequency Questionnaire range from 36 to +47, with higher scores indicating better diet.
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Table 3. Functional Capacity, Risk Factors, Knowledge, and Heart-Health Behaviors at 12 Months, by Condition, and Change From
6 Months (Per Protocol)*
n Estimated Marginal Mean† 95% CI P Value‡ Change From 6 mo§ (MDSD)
Functional capacity (ISWT), m
Wait-list control only 3 415.7 254.3–577.1 25.035.3
Exercise only after 6 mo 8 463.9 360.2–567.6 121.2108.1§
CCR after 6 mo 7 508.4 401.1–615.8 50.072.3
Exercise only 15 497.8 423.2–572.5 9.377.8
CCR 19 444.4 377.6–511.2 15.893.1
Total (SD)k 52 469.8 (161.7) 0.75 18.230.1
Risk factors
BP systolic, mm Hg
Wait-list control only 3 113.6 88.6–138.7 5.07.0
Exercise only after 6 mo 9 127.0 111.9–142.2 3.317.3
CCR after 6 mo 7 124.2 107.5–140.8 15.725.0
Exercise only 15 121.6 110.0–133.2 10.724.6
CCR 19 120.1 109.8–130.5 4.822.8
Total (SD)k 53 121.9 (20.7) 0.89 7.33.8
BP diastolic, mm Hg
Wait-list control only 3 77.3 62.6–92.0 5.07.0
Exercise only after 6 mo 9 79.8 71.0–88.7 0.012.2
CCR after 6 mo 7 84.0 74.2–93.7 14.216.1
Exercise only 15 79.8 73.0–86.6 7.015.3
CCR 19 78.6 72.5–84.6 3.114.9
Total (SD)k 53 79.8 (12.3) 0.90 4.92.4
BMI, kg/m2
Wait-list control only 3 26.4 21.8–31.0 0.30.8
Exercise only after 6 mo 9 26.9 24.1–29.7 0.01.2
CCR after 6 mo 7 26.6 23.5–29.6 0.63.2
Exercise only 15 26.6 24.4–28.7 0.31.6
CCR 19 28.9 27.0–30.9 0.11.5
Total (SD)k 53 27.5 (4.0) 0.46 0.10.7
WC, cm
Wait-list control only 3 93.6 80.8–106.4 1.81.7
Exercise only after 6 mo 9 95.1 87.4–102.8 1.52.8
CCR after 6 mo 7 92.6 84.1–101.1 1.18.3
Exercise only 15 92.9 87.0–98.8 0.073.3
CCR 19 98.2 92.9–103.5 0.14.1
Total (SD)k 53 95.2 (11.2) 0.70 0.32.1
Depressive symptoms (PHQ-9)
Wait-list control only 3 6.2 0.8–11.6 3.63.0
Exercise only after 6 mo 9 2.8 0.3 to 6.1 0.22.9
CCR after 6 mo 7 2.7 0.8 to 6.3 0.74.2
Exercise only 16 5.6 3.2–8.0 1.75.3
Continued
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initially randomized to comprehensive CR as well as those on
the wait-list control who did not elect to participate in CR). No
differences in clinical characteristics were observed.
Sixty (52.2%) participants completed the 12-month assess-
ment (Figure 1; however, hard outcomes were ascertained
from medical records in 100% of the sample). As shown in
Table 3. Continued
n Estimated Marginal Mean† 95% CI P Value‡ Change From 6 mo§ (MDSD)
CCR 19 3.5 1.2–5.7 0.43.9
Total (SD)k 54 4.1 (4.7) 0.41 0.00.9
Disease-related knowledge¶
Wait-list control only 2 30.0¶¶kk** 14.6–45.3 8.56.3
Exercise only after 6 mo 8 46.7††‡‡ 39.0–54.4 2.08.2
CCR after 6 mo 6 63.7¶¶‡‡ 54.7–72.7 6.614.4
Exercise only 16 54.1**# 48.7–59.6 1.410.2
CCR 19 66.5kk††# 57.4–67.6 0.17.2
Total (SD)k 51 56.3 (14.6) <0.001 1.33.0
Health behaviors
Exercise, weekly mean steps
Wait-list control only 3 27 572.7 3120.3–58 265.8 32 277.510 750.1
Exercise only after 6 mo 7 28 849.8 8268.9–49 430.7 12 367.813 458.4§
CCR after 6 mo 7 53 941.2 33 523.7–74 358.6 25 758.853 213.6
Exercise only 16 49 920.5 36 285.8–63 555.2 5282.330 769.6
CCR 18 36 844.6 23 867.1–49 822.0 5127.821 742.7
Total (SD)k 51 41 650.7 (28 913.8) 0.25## 7485.35421.3
Diet***
Wait-list control only 3 4.4 4.2 to 13.1 3.05.5
Exercise only after 6 mo 8 5.3 0.2 to 10.9 2.35.5
CCR after 6 mo 7 4.6 1.2 to 10.3 0.83.8
Exercise only 14 7.5 3.4–11.6 0.27.2
CCR 17 5.1 1.3–8.9 2.47.3
Total (SD)k 49 5.8 (7.3) 0.88 1.21.4
Smoking status (n, % current)†††
Wait-list control only 6 1 16.7 0
Exercise only after 6 mo 9 3 33.3 1
CCR after 6 mo 7 0 0.0 0
Exercise only 16 3 18.8 1
CCR 19 1 5.3 1
Total (SD)k 57 8 (14.0) 0.15 1
BMI indicates body mass index; BP, blood pressure; CCR, comprehensive cardiac rehabilitation; ISWT, incremental shuttle walk test; MD, mean difference; SD, standard deviation; PHQ-9,
Patient Health Questionnaire 9; WC, waist circumference.
*Except the wait-list control arms who elected either cardiac rehabilitation are shown as treated, because program adherence data were not available.
†Adjusted for sex, education, marital status, and sleep apnea.
‡Differences by condition at 12 months. ANCOVA adjusted for sex, education, marital status, and sleep apnea.
§A t test comparing 6 to 12 months, P<0.05 (note that for the pedometer, Wilcoxon tests were performed).
kUnadjusted values.
¶Scores on the Coronary Artery Disease Questionnaire range from 0 to 93, with higher scores indicating better knowledge.
Least signiﬁcant difference post hoc tests from ANCOVA: #P<0.05; **††‡‡P<0.01; §§kk¶¶P<0.001.
##Kruskal–Wallis test also performed, as not normally distributed: P>0.05.
***Scores on the Food Frequency Questionnaire range from 36 to +47, with higher scores indicating better diet.
†††Fisher exact test.
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Table 2, the only differences observed between the sociode-
mographic and clinical characteristics of those retained
versus lost to follow-up were that retained participants more
often were married and had sleep apnea.
Outcomes
Mean scores for functional capacity, risk factor control
(excluding lipids), knowledge, and heart-health behaviors are
shown in Table 3 by arm at 12 months. Table 4 shows the
proportion of participants at outcome target at 12-months by
condition.
Change from 6 to 12 months (ie, difference in outcome
scores between these assessment points) is also shown in
Table 3. A signiﬁcant change was shown only for functional
capacity in controls electing exercise-only CR after 6 months;
those post-CR had no signiﬁcant changes, supporting the
hypothesis of maintenance or lack of decay after the program.
Tests were not performed for wait-list controls who did not
elect CR, given the small retained sample size (n=3).
Differences by condition in all outcomes except morbidity
and mortality at 12 months are also shown in Table 3.
Signiﬁcant differences are shown only in knowledge, with
those who were randomized to CCR having signiﬁcantly
greater knowledge than those in exercise only (at either point)
or wait-list control, and those electing CCR after 6 months
having greater knowledge than wait-list controls and those
electing exercise-only CR. When considered regardless of
time point (Table 5), functional capacity and exercise appear
to have been lower in controls.
There were no signiﬁcant differences in the proportion of
patients seeing a cardiac specialist by group at 6 months
(n=100; 98.0%) or 12 months (n=72, 91.1%; both P>0.05).
Mortality and morbidity are shown by time and condition in
Figure 2 and by mean number of morbid events and
proportion of participants having any morbidity in Table 4.
There were no deaths at 6 months and 2 cardiovascular
deaths at 12 months (1 male and 1 female). Mortality cell
sizes were too small for inferential testing.
As shown, at 6 months, on the basis of intention to treat,
there were signiﬁcantly more hospital readmissions (P=0.03),
nonfatal MIs (P=0.04), and PCIs (P=0.03) in the control group
than among those receiving exercise-only CR (and compared
with those in CCR for PCI, P=0.03; Figure 2). Per protocol,
there were also signiﬁcantly more hospital readmissions in
the wait-list control group than among those receiving
exercise-only CR.
Cell sizes were too small to test for morbidity differences
inferentially at 12 months (ie, only 7 participants elected CCR
after wait listing). The mean number of morbidities was tested
however, and there was no signiﬁcant difference by condition
(Table 4). As shown in Table 5, when examined regardless of
time point, morbidity appeared to be greater in the no-CR arm.
Discussion
In this one of few trials of CR outcomes in LMICs and the only
trial with mortality and morbidity outcomes,24 long-term
follow-up data generally corroborate the beneﬁts achieved
after the program.9 As previously reported, 6-month “soft”
outcomes from this trial demonstrated that CR participation
results in signiﬁcant increases in functional capacity and
reductions in blood pressure from before to after the program
Table 4. Proportion of Participants Meeting Outcome Targets and Total Morbidity at 12 Months by Condition
Initial Randomization Wait List Control (n=39)
Exercise Only
(n=39)
Comprehensive
(n=37)
Total
(N=115)Disposition at 6 mo
No CR
(n=16)
Exercise Only
(n=12)
Comprehensive
(n=11) No CR No CR
Functionally independent (≥7 METs from
ISWT)
0 (0.0) 2 (16.6) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.7)
High BP (no) 13 (81.2) 9 (75.0) 6 (54.5) 28 (71.8) 31 (83.7) 87 (75.6)
Not obese (BMI <30) 12 (75.0) 9 (75.0) 8 (72.7) 27 (69.2) 24 (64.9) 80 (69.6)
Not centrally obese (WC)* 10 (66.7) 7 (58.3) 4 (40.0) 22 (57.9) 18 (50.0) 61 (53.0)
Subclinical depressive symptoms (PHQ-9
<10)
12 (75.0) 11 (91.7) 10 (91.0) 29 (74.3) 31 (83.9) 93 (80.9)
Physically active (≥7500 steps/d) 2 (12.5) 1 (8.3) 2 (18.2) 10 (25.6) 10 (27.0) 25 (21.7)
Morbidities (n) 1.50.7 2.01.1 2.20.9 3.02.3 3.52.2 2.40.7
Morbidities (any) 3 (18.7) 5 (41.6) 8 (72.7) 6 (15.4) 8 (21.6) 30 (26.1)
Data are shown as n (%) or meanSD. BMI indicates body mass index; CR, cardiac rehabilitation; ISWT, incremental shuttle walk test; MET, metabolic equivalent of task; PHQ-9, Patient
Health Questionnaire 9; WC, waist circumference.
*WC <102 cm in men and <88 cm in women.
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and that CCR results in signiﬁcantly greater functional
capacity than no CR.9 Results also demonstrated that CCR
participation results in signiﬁcant increases in patients’
cardiovascular knowledge, exercise, and dietary behaviors,
with greater knowledge, exercise, and diet than among those
not receiving CR and/or participating in exercise-only
programs (G.L. Ghisi et al, unpublished data, 2019). As
reported herein, maintenance of functional capacity, risk
factors, knowledge, and heart-health behaviors after CR was
found at 1 year, as was greater knowledge with CCR than
exercise only or control. Regarding mortality and morbidity,
although there were too few deaths to consider group
differences, morbidity was demonstrated to be signiﬁcantly
lower with any CR compared with none in the short term
(long-term outcomes are still unknown because of limited
sample sizes).
In support of hypotheses, patients randomized to CR had
signiﬁcantly lower rates of hospital readmission, nonfatal MI,
and PCI after the program compared with those who did not
receive CR. The Cochrane review on the effects of CR
showed 18% reductions in hospital admissions with CR5;
however, there were no signiﬁcant reductions in MI or PCI in
that review. It is contended that CR may have greater
beneﬁts in LMICs (including for mortality); the beneﬁts
require further establishment, including magnitude of effect.
These reductions hold meaningful implications for families
(ie, costs for MI care and PCI are unaffordable for most,
particularly given the gross lack of universal healthcare
Table 5. Post-Arm Outcomes, Regardless of Time Point (as Treated)
Arm Wait-List Controls Exercise Only CCR
Assessment Point 6 mo* (n=30) 6 mo (n=25) and 12 mo (n=9) 6 mo (n=26) and 12 mo (n=7)
Primary outcome
Functional capacity, (ISWT), m 394.0171.9 452.3158.4 474.1116.7
Functionally independent (≥7 METs) 1 (3.3) 2 (5.8) 0 (0.0)
Risk factors
BP systolic, mm Hg 120.018.4 118.020.1 119.220.8
BP diastolic, mm Hg 77.015.3 76.612.9 77.113.2
High BP (no) 23 (76.6) 29 (85.3) 26 (78.8)
BMI, kg/m2 27.73.5 28.66.8 28.14.4
Not obese (BMI <30) 22 (56.4) 27 (52.9) 24 (50.0)
WC, cm 95.19.2 95.811.1 95.512.0
Not centrally obese (WC†) 16 (41.0) 23 (45.1) 21 (43.8)
Depressive symptoms& 4.34.6 4.85.9 4.04.8
Subclinical depressive Symptoms (PHQ-9 <10) 28 (93.3) 31 (91.2) 30 (90.9)
Disease-related knowledge‡ 47.015.2 48.713.8 63.69.2
Heart-health behaviors
Exercise (steps/wk) 25 967.618 525.3 31 687.725 149.6 41 506.335 107.3
Physically active (≥7500 steps/d) 4 (13.3) 5 (14.7) 6 (18.2)
Diet§ 6.35.9 6.07.4 7.06.8
Smoker 3 (7.7) 7 (13.7) 2 (4.2)
Hard outcomesk
Mortality 0 (0.0) 1 (2.5) 1 (2.5)
Morbidity, n 5.62.7 2.52.4 2.92.5
Data are shown as n (%) or meanSD. No inferential tests were performed. BMI indicates body mass index; BP, blood pressure; CCR, comprehensive cardiac rehabilitation; ISWT,
incremental shuttle walk test; MET, metabolic equivalent of task; PHQ-9, Patient Health Questionnaire 9; WC, waist circumference.
*Because of potential carryover effects, the exercise-only and CCR participant data from 12-month assessment were not incorporated.
†WC >102 cm for men and >88 cm for women.
‡Scores on the Coronary Artery Disease Questionnaire range from 0 to 93, with higher scores indicating better knowledge.
§Scores on the Food Frequency Questionnaire range from 36 to +47, with higher scores indicating better diet.
kSample size larger because these outcomes were ascertained in all participants regardless of assessment completion.
&Scores on the Patient Health Questionnaire-9 range from 0 to 27, with higher scores indicating greater depressive symptoms.
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coverage) and health systems (ie, cost savings due to
hospital avoidance).
A multisite trial powered for mortality is needed and
appears highly feasible in the middle-income country setting,
considering the high consent rate and the degree of CR
adherence in this trial. Nevertheless, these initial ﬁndings,
corroborated by other studies (primarily nontrials),24,25 sug-
gest that CR is also beneﬁcial for morbidity in LMICs. Results
across all outcomes of this trial support provision of CCR over
exercise-only programs; however, ﬁrmer evidence is needed.
Unfortunately, there is a gross lack of capacity in these
settings.10 This trial bolsters calls for greater access26 so that
patients can achieve these beneﬁts.
Limitations
First, caution is warranted in interpreting the results of this
study. Limits of generalizability, as well as selection and
retention biases up to 6 months, are considered elsewhere.9 At
12 months, retention was only 50% (likely because this
assessment was not planned until after trial accrual), but the
only differences in those retained versus notweremarital status
and sleep apnea, suggesting considerable generalizability.
Second, the trial was not powered for mortality and
morbidity outcomes, nor was it powered for 1-year outcomes.
Group sizes were small at 12 months, as was the number of
events (a longer follow-up period would be preferable).
Although some differences in morbidity were observed, it
cannot be ascertained from this trial whether CR results in
reduced mortality in LMICs. Third, the morbidity outcomes
were not prespeciﬁed.
Fourth, there are measurement issues. Mortality and
morbidity that occurred out of hospital were self-reported.
Although lay language was used, ascertainment error is
possible. Moreover, these outcomes were not adjudicated
formally or blindly by a committee of independent clinicians.
Fifth, there was no blood work at 12 months for ascertain-
ment of dyslipidemia and dysglycemia, and no information
was collected on program adherence in those control
participants who elected to take CR.
Sixth, regarding design, we attempted to consider period
and carryover effects in our analyses; however, there was not
randomization of the wait-list controls to arm at 6 months,
and thus any differences observed could be related to
differences in the nature of participants who elected CR
versus those who did not (ie, sex and education). It was
unfortunate that only 3 participants from the wait-list control
arm did not elect CR and were retained; this sample size was
too small to examine differences, and thus comparison to a
no-CR control for the soft outcomes was not possible at the
12-month assessment. Finally, because primary, secondary,
and tertiary outcomes were considered in this article, multiple
comparisons were performed, possibly increasing the chances
of type I error.
Conclusion
CR participation is associated with lower morbidity and long-
term maintenance of functional capacity, risk factors, and
heart-health behaviors, as well as greater cardiovascular
knowledge compared with no CR. These results, together with
the primary and secondary outcomes of the trial demonstrat-
ing clinically signiﬁcant improvements in functional capacity
and risk factor management, conﬁrm the need for greater
implementation of CR in Brazil and other LMICs.
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